Genta Incorporated (GETA.OB) Release: New Clinical Trial Confirms the Activity of Tesetaxel in Patients With Advanced Gastric Cancer
1/19/2012 9:22:11 AM
BERKELEY HEIGHTS, N.J., Jan. 19, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA.OB) today announced results from the Company's Phase 2b, confirmatory clinical trial of tesetaxel in patients with advanced gastric cancer. The trial is lead by investigators from M.D. Anderson Cancer Center, Houston, TX, in collaboration with Northwestern University, Chicago, IL, University of Pennsylvania, Philadelphia, PA, and the Severance Hospital, Seoul, Korea. The data are being presented this week at the GI Cancer Symposium in San Francisco, CA, sponsored by the American Society of Clinical Oncology (ASCO).